GT Biopharma Inc Down 3.44% To $4.33 After Earnings Beat

GT Biopharma Inc (GTBP) said after close Tuesday that it lost $2.14 per share in quarter four 2023. The company reported $0.00 in revenue

In the same quarter a year ago, the company lost $5.4 per share on revenue of $0.00.

The stock is down 3.44% to $4.33 after the report.

The firm's higher revenue growth to earnings signals that the firm has not been able to reduce costs and has seen its profit margin decrease.

The average recommendation from Wall Street analysts was a Strong Buy which may get revised based on this new data.

Trading in the five days leading up to the report earned GT Biopharma Inc a Neutral Sentiment Rank from InvestorsObserver.

Prior to the report, InvestorsObserver gave the stock an overall score of 36. Meanwhile, the average Wall Street analyst rated the stock a Strong Buy.

GT Biopharma Inc is an immuno-oncology company operating in the United States. It is engaged in discovering, developing and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its key drug candidates are OXS-2175, targeting the treatment of triple-negative breast cancer; OXS-4235, targets the treatment of multiple myeloma and associated osteolytic lesions; and OXS-1550, targets cancer cells expressing the CD19 receptor and CD22 receptor. Its TriKE and TetraKE platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.